Menu
  • Home
  • About Us
    • About LumiThera
    • Management Team
    • Board of Directors
    • Careers
  • The Science
    • About Photobiomodulation
    • About AMD
    • Clinical Research
    • Articles
  • Products
    • Valeda™
  • News & Events
    • Press Releases
    • Events
  • Contact Us
Developing Photobiomodulation Treatments for Ocular Diseases and Disorders
Improves Visual Acuity
Improves Contrast Sensitivity
Reduces Central Drusen Volume

LumiThera is a medical device company at the forefront in the development of photobiomodulation (PBM) treatment protocols for patients with dry AMD.

Age-related macular degeneration (AMD) is the leading cause of blindness in adults over 65. There are two forms of AMD: dry and wet. Approximately 90% of patients with AMD have the dry form and 10% have the wet form.

CAUTION Investigational device. Limited by Federal (or United States) law to investigational use.

  • About Us

    Developing
    treatments
    to preserve &
    improve vision
  • Products

    Developing PBM
    devices to treat ocular
    diseases and disorders
  • The Science

    Learn about the
    science supporting
    the use of PBM
  • Research

    Learn about the
    ongoing clinical studies
Let's get the conversation started
Contact Us Subscribe
  • Home
  • About Us
  • The Science
  • Products
  • News & Info
  • Contact Us
  • Privacy Policy
  • Terms of Service
  • Terms and Conditions of Sale
  • End User License Agreement
© 2018 LumiThera, Inc.
All Rights Reserved
Not for sale
in the USA
CE 0086
2797
MKT-0021 REVC

Please select your country or region

  • USUSA (& Rest of World) Healthcare Professionals
  • EUEU Healthcare Professionals
  • USEcuadorian Healthcare Professionals
  • USColombian Healthcare Professionals
  • TRTurkish Healthcare Professionals

select your country or region Current country flag